{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:13:18Z","timestamp":1791216798709,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00059-009-3305-7","type":"journal-article","created":{"date-parts":[[2011,1,21]],"date-time":"2011-01-21T03:52:36Z","timestamp":1295581956000},"page":"607-613","source":"Crossref","is-referenced-by-count":41,"title":["CRP in Cardiovascular Disease","CRP bei kardiovaskul\u00e4ren Erkrankungen"],"prefix":"10.1007","volume":"34","author":[{"given":"Mahir","family":"Karakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,13]]},"reference":[{"key":"3305_CR1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","volume":"25","author":"C. Arnaud","year":"2005","unstructured":"Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005;25:1231\u20131236.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3305_CR2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","volume":"350","author":"J. Danesh","year":"2004","unstructured":"Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387\u20131397.","journal-title":"N Engl J Med"},{"key":"3305_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","volume":"302","author":"P. Elliott","year":"2009","unstructured":"Elliott P, Chambless JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37\u201348.","journal-title":"JAMA"},{"key":"3305_CR4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/CIRCULATIONAHA.108.816769","volume":"119","author":"E.S. Ford","year":"2009","unstructured":"Ford ES, Zhao G, Mokdad AH. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation 2009;119:1108\u20131115.","journal-title":"Circulation"},{"key":"3305_CR5","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","volume":"360","author":"R.J. Glynn","year":"2009","unstructured":"Glynn RJ, Danielson E, et al. A randomized trial in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851\u20131861.","journal-title":"N Engl J Med"},{"key":"3305_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","volume":"119","author":"M.A. Hlatky","year":"2009","unstructured":"Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408\u20132416.","journal-title":"Circulation"},{"key":"3305_CR7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.HYP.0000130484.20501.df","volume":"44","author":"I. Jialal","year":"2004","unstructured":"Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6\u201311.","journal-title":"Hypertension"},{"key":"3305_CR8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2350-10-46","volume":"10","author":"M. Karakas","year":"2009","unstructured":"Karakas M, Hoffmann MM, Vollmert C. et al. Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations. BMC Med Genet 2009;10:46.","journal-title":"BMC Med Genet"},{"key":"3305_CR9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijcard.2004.05.019","volume":"98","author":"W. Koenig","year":"2005","unstructured":"Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol 2005;98:199\u2013206.","journal-title":"Int J Cardiol"},{"key":"3305_CR10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1373\/clinchem.2008.115915","volume":"55","author":"W. Koenig","year":"2009","unstructured":"Koenig W. Is hsCRP back on board? Implications from the JUPITER trial. Clin Chem 2009;55:216\u2013218.","journal-title":"Clin Chem"},{"key":"3305_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.ATV.0000251503.35795.4f","volume":"27","author":"W. Koenig","year":"2007","unstructured":"Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15\u201326.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3305_CR12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1161\/01.CIR.0000120707.98922.E3","volume":"109","author":"W. Koenig","year":"2004","unstructured":"Koenig W, L\u00f6wel H, Baumert J, et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349\u20131353.","journal-title":"Circulation"},{"key":"3305_CR13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.CIR.99.2.237","volume":"99","author":"W. Koenig","year":"1999","unstructured":"Koenig W, Sund M, Fr\u00f6hlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237\u2013242.","journal-title":"Circulation"},{"key":"3305_CR14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P. Libby","year":"2002","unstructured":"Libby P. Inflammation in atherosclerosis. Nature 2002;420:868\u2013874.","journal-title":"Nature"},{"key":"3305_CR15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199408183310701","volume":"331","author":"G. Liuzzo","year":"1994","unstructured":"Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417\u2013424.","journal-title":"N Engl J Med"},{"key":"3305_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.2009.943","volume":"302","author":"O. Melander","year":"2009","unstructured":"Melander O, Newton-Chec C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49\u201357.","journal-title":"JAMA"},{"key":"3305_CR17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1373\/clinchem.2008.109728","volume":"55","author":"S. Mora","year":"2009","unstructured":"Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009;55:219\u2013228.","journal-title":"Clin Chem"},{"key":"3305_CR18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/ncpcardio1322","volume":"5","author":"K. Musunuru","year":"2008","unstructured":"Musunuru K, Kral BG, Blumenthal RS, et al. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med 2008;5:621\u2013635.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"3305_CR19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1373\/clinchem.2008.115899","volume":"55","author":"NACB LMPG Committee Members","year":"2009","unstructured":"NACB LMPG Committee Members, Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009;55:378\u2013384.","journal-title":"Clin Chem"},{"key":"3305_CR20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCOUTCOMES.109.868299","volume":"2","author":"P.M. Ridker","year":"2009","unstructured":"Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes 2009;2:279\u2013285.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3305_CR21","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"P.M. Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195\u20132207.","journal-title":"N Engl J Med"},{"key":"3305_CR22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"P.M. Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca F, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175\u20131182.","journal-title":"Lancet"},{"key":"3305_CR23","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"P.M. Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, et al., for the Air Force\/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959\u20131965.","journal-title":"N Engl J Med"},{"key":"3305_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/CIRCOUTCOMES.108.832592","volume":"2","author":"E.S. Spatz","year":"2009","unstructured":"Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999\u20132004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2009;2:41\u201348.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3305_CR25","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","volume":"359","author":"J. Zacho","year":"2008","unstructured":"Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897\u20131908.","journal-title":"N Engl J Med"},{"key":"3305_CR26","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa0707064","volume":"358","author":"B. Zethelius","year":"2008","unstructured":"Zethelius B, Berglund L, Sundstr\u00f6m J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107\u20132116.","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-009-3305-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-009-3305-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-009-3305-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:56:29Z","timestamp":1558540589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-009-3305-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["3305"],"URL":"https:\/\/doi.org\/10.1007\/s00059-009-3305-7","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}